Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrand, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study

A Wöckel; Brucker; J Falbrede; H Forstbauer; T Göhler; O Hoffmann; C Jackisch; J Janssen; A Köhler; K Lüdtke-Heckenkamp; D Lüftner; F Marme; A Nusch; T Reimer; C Ross; M Schmidt; R Weide; P Fasching

Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrand, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study

A Wöckel
, Brucker
, J Falbrede
, H Forstbauer
, T Göhler
, O Hoffmann
, C Jackisch
, J Janssen
, A Köhler
, K Lüdtke-Heckenkamp
, D Lüftner
, F Marme
, A Nusch
, T Reimer
, C Ross
, M Schmidt
, R Weide
, P Fasching

Universitätsklinik für Frauenheilkunde und Geburtshilfe

Publikation: Konferenzbeitrag › Poster

Originalsprache	undefiniert/unbekannt
Publikationsstatus	Veröffentlicht - 2020
Veranstaltung	SABCS - virtuell Dauer: 8 Dez. 2020 → 12 Dez. 2020

Konferenz mit wissenschaftlichem Inhalt

Konferenz mit wissenschaftlichem Inhalt	SABCS
Ort	virtuell
Zeitraum	8/12/20 → 12/12/20

1 Abstrakt

Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrand, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study
Wöckel, A., Brucker, Falbrede, J., Forstbauer, H., Göhler, T., Hoffmann, O., Jackisch, C., Janssen, J., Köhler, A., Lüdtke-Heckenkamp, K., Lüftner, D., Marme, F., Nusch, A., Reimer, T., Ross, C., Schmidt, M., Weide, R. & Fasching, P., 2020.
Publikation: Konferenzbeitrag › Abstrakt

Dieses zitieren

Wöckel, A., Brucker, Falbrede, J., Forstbauer, H., Göhler, T., Hoffmann, O., Jackisch, C., Janssen, J., Köhler, A., Lüdtke-Heckenkamp, K., Lüftner, D., Marme, F., Nusch, A., Reimer, T., Ross, C., Schmidt, M., Weide, R., & Fasching, P. (2020). Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrand, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study. Postersitzung präsentiert bei SABCS, virtuell.

@conference{2ecebc8ab0b6433bbf3a391265c705ff,

title = "Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrand, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study",

author = "A W{\"o}ckel and Brucker and J Falbrede and H Forstbauer and T G{\"o}hler and O Hoffmann and C Jackisch and J Janssen and A K{\"o}hler and K L{\"u}dtke-Heckenkamp and D L{\"u}ftner and F Marme and A Nusch and T Reimer and C Ross and M Schmidt and R Weide and P Fasching",

year = "2020",

language = "Undefined/Unknown",

note = "SABCS ; Conference date: 08-12-2020 Through 12-12-2020",

}

Wöckel, A, Brucker, Falbrede, J, Forstbauer, H, Göhler, T, Hoffmann, O, Jackisch, C, Janssen, J, Köhler, A, Lüdtke-Heckenkamp, K, Lüftner, D, Marme, F, Nusch, A, Reimer, T, Ross, C, Schmidt, M, Weide, R & Fasching, P 2020, 'Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrand, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study', SABCS, virtuell, 8/12/20 - 12/12/20.

Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrand, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study. / Wöckel, A; Brucker; Falbrede, J et al.
2020. Postersitzung präsentiert bei SABCS, virtuell.

Publikation: Konferenzbeitrag › Poster

TY - CONF

T1 - Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrand, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study

AU - Wöckel, A

AU - Brucker, null

AU - Falbrede, J

AU - Forstbauer, H

AU - Göhler, T

AU - Hoffmann, O

AU - Jackisch, C

AU - Janssen, J

AU - Köhler, A

AU - Lüdtke-Heckenkamp, K

AU - Lüftner, D

AU - Marme, F

AU - Nusch, A

AU - Reimer, T

AU - Ross, C

AU - Schmidt, M

AU - Weide, R

AU - Fasching, P

PY - 2020

Y1 - 2020

M3 - Poster

T2 - SABCS

Y2 - 8 December 2020 through 12 December 2020

ER -

Wöckel A, Brucker, Falbrede J, Forstbauer H, Göhler T, Hoffmann O et al.. Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrand, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study. 2020. Postersitzung präsentiert bei SABCS, virtuell.

Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrand, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study

Konferenz mit wissenschaftlichem Inhalt

Publikationen

Real-world efficacy of ribociclib + aromatase inhibitor/fulvestrand, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study

Dieses zitieren